title: Distribution of APOE genotypes in a memory clinic cohort.
abstract: OBJECTIVE
  To describe the distribution of apolipoprotein E (APOE) genotypes in a cohort of memory clinic patients.
  
  
  METHODS
  We included 749 memory clinic patients. Diagnoses were made in a multidisciplinary consensus meeting and the APOE genotype was determined. The community-based cohort of the Longitudinal Aging Study Amsterdam was used as control population (n = 2,233).
  
  
  RESULTS
  In the memory clinic sample, there were 173 patients with subjective complaints, 125 patients with mild cognitive impairment (MCI), 251 patients with Alzheimer disease (AD), 107 patients with another type of dementia, and 93 patients with another neurologic or psychiatric diagnosis. The APOE allele distribution differed among groups. There was no difference in the prevalence of the epsilon2 allele, but there were differences in distribution of the epsilon3 and epsilon4 alleles. Compared with the control population (15%), the prevalence of APOE epsilon4 was increased among patients with subjective complaints (22%), MCI (36%), AD (42%) and other types of dementia (25%).
  
  
  CONCLUSIONS
  We observed an increased prevalence of APOE epsilon4 in patients with MCI and subjective complaints. This finding is of great clinical importance as nondemented patients positive for APOE epsilon4 could be identified as being at genetic risk of AD, and for that reason monitored more closely.
authors.affiliation: Alzheimer Center, Department of Neurology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands.
authors.forename: W M
authors.initials: WM
authors.lastname: van der Flier
authors.forename: Y A L
authors.initials: YA
authors.lastname: Pijnenburg
authors.forename: S N M
authors.initials: SN
authors.lastname: Schoonenboom
authors.forename: M G
authors.initials: MG
authors.lastname: Dik
authors.forename: M A
authors.initials: MA
authors.lastname: Blankenstein
authors.forename: P
authors.initials: P
authors.lastname: Scheltens
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000453:epidemiology / Q000235:genetics; D000554:Ambulatory Care Facilities / Q000706:statistics & numerical data; D053329:Apolipoprotein E2 / Q000235:genetics; D053318:Apolipoprotein E3 / Q000235:genetics; D053327:Apolipoprotein E4 / Q000235:genetics; D001057:Apolipoproteins E / Q000235:genetics*; D003072:Cognition Disorders / Q000453:epidemiology* / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease / Q000453:epidemiology; D005838:Genotype; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008569:Memory Disorders / Q000453:epidemiology* / Q000235:genetics*; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D015995:Prevalence; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D053329:Apolipoprotein E2; D053318:Apolipoprotein E3; D053327:Apolipoprotein E4; D001057:Apolipoproteins E